Senior Optometrist Northeastern Eye Institute Scranton, Pennsylvania, United States
Disclosure(s): No relevant disclosure to display
Disclosure(s):
Joeseph Shovlin: No relevant disclosure to display
New molecularly targeted cancer therapies have emerged as an option above conventional cytotoxic chemotherapy agents. These agents have distinct systemic and eye related adverse side effects. The adverse events can be quite severe and potentially result in a vision threatening experience and, in most cases, has to be discontinued to preserve vision. Clinicians need to be aware of potential side effects and be able to identify them early for adequate management of these challenging cases.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Become familiar with new cancer treatment breakthroughs.
Differentiate between toxicities from cancer treatment agents, effects of the malignancy and metastatic disease.
Become familiar with the various targeted therapy agents used and the compartment of the eye involved in eye related adverse events
Recognize when the oncologist or other health care provider might want to reduce or delay dosing these agents, or unfortunately know when they must be discontinued to preserve vision.
Gain ability to alert individuals who are undergoing treatment on what to look for in potential toxicity of various agents.
Understand new agents in the pipeline and future treatment options soon to be investigated on a full-scale FAD pre-market approval basis.